首页> 外文期刊>Progress in Artificial Intelligence >Design of experiment (DoE)-driven in vitro and in vivo uptake studies of exosomes for pancreatic cancer delivery enabled by copper-free click chemistry-based labelling
【24h】

Design of experiment (DoE)-driven in vitro and in vivo uptake studies of exosomes for pancreatic cancer delivery enabled by copper-free click chemistry-based labelling

机译:在体外实验(DOE)的设计和体内摄取性研究通过铜无咔哒化化学标记使得胰腺癌递送的外来体

获取原文
获取原文并翻译 | 示例
           

摘要

Exosomes (Exo)-based therapy holds promise for treatment of lethal pancreatic cancer (PC). Limited understanding of key factors affecting Exo uptake in PC cells restricts better design of Exo-based therapy. This work aims to study the uptake properties of different Exo by PC cells. Exo from pancreatic carcinoma, melanoma and non-cancer cell lines were isolated and characterised for yield, size, morphology and exosomal marker expression. Isolated Exo were fluorescently labelled using a novel in-house developed method based on copper-free click chemistry to enable intracellular tracking and uptake quantification in cells. Important factors influencing Exo uptake were initially predicted by Design of Experiments (DoE) approach to facilitate subsequent actual experimental investigations. Uptake of all Exo types by PC cells (PANC-1) showed time- and dose-dependence as predicted by the DoE model. PANC-1 cell-derived exosomes (PANC-1 Exo) showed significantly higher uptake in PANC-1 cells than that of other Exo types at the longest incubation time and highest Exo dose. In vivo biodistribution studies in subcutaneous tumour-bearing mice similarly showed favoured accumulation of PANC-1 Exo in self-tissue (i.e. PANC-1 tumour mass) over the more vascularised melanoma (B16-F10) tumours, suggesting intrinsic tropism of PC-derived Exo for their parent cells. This study provides a simple, universal and reliable surface modification approach via click chemistry for in vitro and in vivo exosome uptake studies and can serve as a basis for a rationalised design approach for pre-clinical Exo cancer therapies.
机译:基于外泌体(EXO)的疗法持有治疗致命胰腺癌(PC)的承担。有限地了解影响PC细胞中exo摄取的关键因素限制了基于外胃的疗法设计。这项工作旨在通过PC细胞研究不同EXO的摄取性质。从胰腺癌,黑色素瘤和非癌细胞系中分离出并表征了产率,大小,形态学和外泌体标志物表达。使用基于无铜咔哒化学的新型内部开发方法荧光标记孤立的EXO,以使细胞内的细胞内跟踪和摄取量化能够。通过实验(DOE)方法的设计,最初预测了影响EXO摄取的重要因素,以促进随后的实际实验研究。通过PC细胞(PANC-1)的所有EXO类型的摄取显示,随着DOE模型预测的时间和剂量依赖性。 Panc-1细胞衍生的外泌体(PANC-1 EXO)在最长孵育时间和最高exo剂量下表现出Panc-1细胞的显着更高的摄取。在皮下肿瘤的小鼠体内生物分布研究同样地显示了在更血管化的黑色素瘤(B16-F10)肿瘤上的自组织(即Panc-1肿瘤质量)中的Panc-1 EXO的青睐积累,表明PC衍生的内在抗性exo为他们的父母细胞。本研究提供了一种简单,普遍且可靠的表面改性方法,可通过单击体外和体内外泌体摄取研究,作为临床前癌症疗法合理设计方法的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号